Exogenous GLP-1 improves gastric compliance in a dose-dependent manner (Schirra et al., 2002), reduces the frequency and amplitude of gastric antrum and duodenum contraction, inhibits the contractile force of gastric antrum and duodenum, increases pyloric tension, and stimulates pyloric tetanic and phase motion (Schirra et al., 2000)
In obese (OB/OB) mice, GLP-1 reduces ER stress in adipose tissue, improving insulin sensitivity through unresolved mechanisms (Yi et al., 2023)
Compounded medications not FDA-approved and does not undergo FDA review for safety, effectiveness, or manufacturing
Preparing for these relationship dynamics helps navigate them more successfully
Because the majority of diabetes patients have T2DM, prescribing practices and clinical guidelines consistently prioritize GLP-1 therapy for this group, ensuring that T2DM remains the leading indication driving revenue and market share within the global GLP-1 receptor agonist segment
Orlistats main drawback is digestive: because the unabsorbed fat has to go somewhere, side effects like oily or loose bowel movements are common (especially after fatty meals)
